Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Effectiveness of mRNA-BNT162b2, mRNA-1273, and ChAdOx1 nCoV-19 vaccines against COVID-19 in healthcare workers: an observational study using surveillance data
Christophe Paris, Sophie Perrin, Stéphanie Hamonic, et al.
Clinical Microbiology and Infection (2021) Vol. 27, Iss. 11, pp. 1699.e5-1699.e8
Open Access | Times Cited: 59

Showing 1-25 of 59 citing articles:

Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against SARS-CoV-2 and variants of concern: a narrative review
Thibault Fiolet, Yousra Kherabi, Conor-James MacDonald, et al.
Clinical Microbiology and Infection (2021) Vol. 28, Iss. 2, pp. 202-221
Open Access | Times Cited: 820
Advances in COVID-19 mRNA vaccine development
Enyue Fang, Xiaohui Liu, Miao Li, et al.
Signal Transduction and Targeted Therapy (2022) Vol. 7, Iss. 1
Open Access | Times Cited: 395
Effectiveness of mRNA-1273 against delta, mu, and other emerging variants of SARS-CoV-2: test negative case-control study
Katia Bruxvoort, Lina S. Sy, Lei Qian, et al.
BMJ (2021), pp. e068848-e068848
Open Access | Times Cited: 222
SARS-CoV-2 vaccine effectiveness against infection, symptomatic and severe COVID-19: a systematic review and meta-analysis
Paddy Ssentongo, Anna E. Ssentongo, Navya Voleti, et al.
BMC Infectious Diseases (2022) Vol. 22, Iss. 1
Open Access | Times Cited: 219
Covid-19 vaccine immunogenicity in people living with HIV-1
Lauriane Nault, Lorie Marchitto, Guillaume Goyette, et al.
Vaccine (2022) Vol. 40, Iss. 26, pp. 3633-3637
Open Access | Times Cited: 68
Real-world effectiveness of the mRNA-1273 vaccine against COVID-19: Interim results from a prospective observational cohort study
Katia Bruxvoort, Lina S. Sy, Lei Qian, et al.
The Lancet Regional Health - Americas (2021) Vol. 6, pp. 100134-100134
Open Access | Times Cited: 83
Effectiveness of rAd26-rAd5, ChAdOx1 nCoV-19, and BBIBP-CorV vaccines for risk of infection with SARS-CoV-2 and death due to COVID-19 in people older than 60 years in Argentina: a test-negative, case-control, and retrospective longitudinal study
Analía Rearte, Juan Manuel Castelli, Ramiro Rearte, et al.
The Lancet (2022) Vol. 399, Iss. 10331, pp. 1254-1264
Open Access | Times Cited: 58
Risk of Vaccine Breakthrough SARS-CoV-2 Infection and Associated Factors in Healthcare Workers of Trieste Teaching Hospitals (North-Eastern Italy)
Paolo Basso, Corrado Negro, Luca Cegolon, et al.
Viruses (2022) Vol. 14, Iss. 2, pp. 336-336
Open Access | Times Cited: 38
Dynamics of anti-Spike IgG antibody level after the second BNT162b2 COVID-19 vaccination in health care workers
Hiroaki Ikezaki, Hideyuki Nomura, Nobuyuki Shimono
Journal of Infection and Chemotherapy (2022) Vol. 28, Iss. 6, pp. 802-805
Open Access | Times Cited: 30
Mechanistic models of humoral kinetics following COVID-19 vaccination
Daniel Stocks, Amy Thomas, Adam Finn, et al.
Journal of The Royal Society Interface (2025) Vol. 22, Iss. 222
Open Access
Inactivated SARS-CoV-2 vaccines elicit immunogenicity and T-cell responses in people living with HIV
Zhengchao Lv, Qin Li, Zaixiong Feng, et al.
International Immunopharmacology (2021) Vol. 102, pp. 108383-108383
Open Access | Times Cited: 36
Comparison of Neutralizing Antibody Responses at 6 Months Post Vaccination with BNT162b2 and AZD1222
Evangelos Terpos, Vangelis Karalis, Ioannis Ntanasis‐Stathopoulos, et al.
Biomedicines (2022) Vol. 10, Iss. 2, pp. 338-338
Open Access | Times Cited: 26
Platform adaptive trial of novel antivirals for early treatment of COVID-19 In the community (PANORAMIC): protocol for a randomised, controlled, open-label, adaptive platform trial of community novel antiviral treatment of COVID-19 in people at increased risk of more severe disease
Oghenekome Gbinigie, Emma Ogburn, Julie Allen, et al.
BMJ Open (2023) Vol. 13, Iss. 8, pp. e069176-e069176
Open Access | Times Cited: 15
Occurrence of COVID‐19 in priority groups receiving ChAdOx1 nCoV‐19 coronavirus vaccine (recombinant): A preliminary analysis from north India
Upinder Kaur, Sapna Bala, Bisweswar Ojha, et al.
Journal of Medical Virology (2021) Vol. 94, Iss. 1, pp. 407-412
Open Access | Times Cited: 30
Real-World Effectiveness of the mRNA-1273 Vaccine Against COVID-19: Interim Results from a Prospective Observational Cohort Study
Katia Bruxvoort, Lina S. Sy, Lei Qian, et al.
SSRN Electronic Journal (2021)
Closed Access | Times Cited: 30
Comparative effectiveness of ChAdOx1 versus BNT162b2 covid-19 vaccines in health and social care workers in England: cohort study using OpenSAFELY
William Hulme, Elizabeth Williamson, Amelia Green, et al.
BMJ (2022), pp. e068946-e068946
Open Access | Times Cited: 19
Vaccine efficacy against SARS-CoV-2 for Pfizer BioNTech, Moderna, and AstraZeneca vaccines: a systematic review
Lia Reynolds, Cate Dewey, Ghaid Asfour, et al.
Frontiers in Public Health (2023) Vol. 11
Open Access | Times Cited: 11
One-year follow-up of the immunogenicity and safety of a primary series of the NVX-CoV2373 (TAK-019) vaccine in healthy Japanese adults: Final report of a phase I/II randomized controlled trial
Kenji Kuriyama, Kyoko Murakami, Kenkichi Sugiura, et al.
Vaccine (2024) Vol. 42, Iss. 6, pp. 1319-1325
Open Access | Times Cited: 3
Durability of mRNA-1273 against COVID-19 in the time of Delta: Interim results from an observational cohort study
Ana Florea, Lina S. Sy, Yi Luo, et al.
PLoS ONE (2022) Vol. 17, Iss. 4, pp. e0267824-e0267824
Open Access | Times Cited: 18
Effectiveness of mRNA-1273 against Delta, Mu, and other emerging variants
Katia Bruxvoort, Lina S. Sy, Lei Qian, et al.
medRxiv (Cold Spring Harbor Laboratory) (2021)
Open Access | Times Cited: 22
Immunoinformatics mapping of potential epitopes in SARS-CoV-2 structural proteins
Yengkhom Damayanti Devi, Himanshu Ballav Goswami, Sushmita Konwar, et al.
PLoS ONE (2021) Vol. 16, Iss. 11, pp. e0258645-e0258645
Open Access | Times Cited: 21
Guidelines for Infection Control and Burnout Prevention in Healthcare Workers Responding to COVID-19
Se Yoon Park, Hae Suk Cheong, Ki Tae Kwon, et al.
Infection and Chemotherapy (2023) Vol. 55, Iss. 1, pp. 150-150
Open Access | Times Cited: 8
Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against SARS-CoV-2 and variants of concern
Thibault Fiolet, Yousra Kherabi, Conor MacDonald, et al.
(2021)
Closed Access | Times Cited: 19
Effectiveness of BNT162b2 and mRNA-1273 Vaccines against COVID-19 Infection: A Meta-Analysis of Test-Negative Design Studies
Shuailei Chang, Hongbo Liu, Jian Wu, et al.
Vaccines (2022) Vol. 10, Iss. 3, pp. 469-469
Open Access | Times Cited: 12
COVID-19 vaccination efficacy in numbers including SARS-CoV-2 variants and age comparison: a meta-analysis of randomized clinical trials
Marharyta Sobczak, Rafał Pawliczak
Annals of Clinical Microbiology and Antimicrobials (2022) Vol. 21, Iss. 1
Open Access | Times Cited: 11
Page 1 - Next Page

Scroll to top